Emvolio

Emvolio, Inc. was a biotechnology company based in Oceanside, California, and a subsidiary of Therapeutic Solutions International (TSOI). Founded in 2016, the company was dedicated to developing and commercializing a suite of proprietary immunotherapy technologies for the treatment of various forms of cancer. Its pipeline included diverse candidates such as StemVacs, a cancer stem cell vaccine, and innaMune, a cytokine-based therapy designed to modulate the innate immune system. While the company aimed to revolutionize personalized cancer treatment by targeting tumors at multiple biological levels, it is currently classified as inactive or deadpooled, with its core intellectual property and development programs largely managed by its parent company, TSOI.